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Due to intensiﬁed research over the past decade, the Hedgehog (HH) pathway has been identiﬁed as a pivotal defect implicated
in roughly 25% of all cancers. As one of the most frequent cancer worldwide, the development of Basal cell carcinoma (BCC)
due to activation of the HH pathway has been convincingly demonstrated. Thus the discovery of this central tumor-promoting
signalling pathway has not only revolutionized the understanding of BCC carcinogenesis but has also enabled the development
of a completely novel therapeutic approach. Targeting just a few of several potential mutations, HH inhibitors such as GDC-
0449 achieved already the ﬁrst promising results in metastatic or locally advanced BCC. This paper summarizes the current
understanding of BCC carcinogenesis and describes the current “mechanism-based” therapeutic strategies.
1.Introduction
BCC, the most commonly diagnosed skin cancer in persons
of fair complexion, has become the focus of intensiﬁed
translational debate lately. Following the circumstantial
evidence that ewes gave birth to cyclopic and malformed
lambs after nibbling on Veratrum californicum, a Corn
lily, the causative teratogenic compound, cyclopamine, was
discovered [1, 2]. Increased research on this agenda and the
understanding of its functioning led to the discovery of the
Hedgehog signalling pathway (HH) as an essential cascade
in embryonic development [3] .P r o o fo fas p e c i ﬁ cm u t a t i o n
in BCC’s Hedgehog pathway showed for the ﬁrst time that
an aberrant HH signalling is also strongly implicated in
cancerogenesis of skin tumors [4]. Though a wide range
of eﬃcient therapeutic options are well established in
the treatment of sporadic BCC, the newly developed HH
inhibitors andﬁrststudyresultsgiverisetoacurativeoreven
secondary-prophylactic approachin hereditary, advanced, or
even metastatic variants.
This paper summarizes the current knowledge of clinical
aspects and the molecular pathogenesis of this form of skin
cancer. Moreover, we discuss current and future therapies
that are needed in order to allow eﬃcient treatment of BCC
in complicated localization, in patients with multiple tumors
or genetic disease predisposing for BCC development, or
patients that are not eligible for surgery.
2.Epidemiology and ClinicalAspects
First described by Krompecher in 1900 as “carcinoma
epitheliale adenoides” [5] and named after its morphological
aﬃnity to the normal cell of the basal layer, BCC is the
most common keratinocyte skin cancer (KSC) in persons
of Caucasian ancestry. Although it presumably develops
from epidermal stem cells of the outer root sheat of the
hair follikel, the precise origin of BCC is still unknown
thus far [6, 7]. Its incidence is estimated up to 100 cases
per 100,000 and even higher depending on geographical or
complexion disparities. Hence, BCC as well as other KSCs
are often excluded from cancer-registry statistics, thereby
underestimating the socioeconomic burden of this form of
cancer [8–10] .M o r ec o m m o ni nm e nt h a ni nw o m e n ,B C C2 Journal of Skin Cancer
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Figure 1: Risk factors of BCC, adapted from Rubin et al. [16].
usually arises at an average age of 60 years. Apart from the
environmental exposure to arsenic, ionizing radiation, oral
methoxsalen (psoralen), and immunosuppressive therapy
such as in organ transplant recipients [11, 12], persons with
a fair skin type-I complexion (including red or blonde hair,
light coloured eyes, freckling) and people with a history
of intermittent sun exposure and severe sunburn during
childhood are at highest risk [13]. In particular ultraviolet
(UV) irradiation in inverse correlation with reduced or
impaired skin pigmentation is generally considered to be the
major risk factor of basal cell carcinoma [14, 15]. Depending
on timing (childhood, adolescence), pattern (intermittent,
continuous), source (natural, artiﬁcial), and amount (cumu-
lative sun exposure), its impact on BCC development is,
however, far more complex and needs further detailed study
[16]. Though the rates are still highest for the naturally sun
exposed skin of elderly man, the trend over the past decade
is clearly towards an increasing incidence of BCC in younger
women due to excessive tanning and sunbed use (Figure 1)
[17].
The majority of sporadically occurring BCCs arise in
sun-exposed areas with over 80% of all cases developing on
the head and neck. Unlike squamous cell carcinoma (SCC),
BCCs do not have detectable precursor lesions and usually
present themselves de novo as a palpable, localised, translu-
cent tumour with overlying teleangiectasias. For hitherto
unknown reasons, they diﬀer in three main clinical as well as
histologicalphenotypes:thenodularBCCexhibitingapearly
rolled border at times with central crusting and ulceration,
the superﬁcial subtype with its scaly erythematous patch
or plaque-like appearance and the sclerosing, inﬁltrative, or
morpheaform variant that clinically presents as a scar-like,
centrally atrophic, whitish, indurate tumour with indistinct
margins. Frequently, those three histological subtypes are
mixed.Inaddition toaggressiveBCCssuchastheinﬁltrative,
micronodular, or basosquamous subtypes, uncommon BCC
variantsincludetheclear-cell,granular-cell,oradamantinoid
variants, and adnexal diﬀerentiation. Pigmented tumours,
known to carry p53 mutations [18], may mimic several
diﬀerential diagnoses including melanoma and therefore
need to be conﬁrmed by biopsy. Although erosion and
ulceration can develop quite early, especially in the nodular
variant, sporadic BCC is in general a slow growing, delayed
inﬁltrating, or destructive tumour that, even in view of other
risk factors in terms of a large diameter >2cm, incomplete
incisionandperivascularinvolvement,metastasesonlyoccur
after years of existence in 0.55% of all cases [19]. Once
metastasisedinregionallymphnodesfollowedbybone,liver,
and lung, the prognosis is poor with a mean survival of at
most 3.6 years after diagnosis [19, 20].
In contrast to the sporadic variant of BCC, a hereditary
disorder, also known as Gorlin syndrome or basal cell
nevus syndrome (BCNS), exhibits a marked propensity to
develop numerous BCCs already during adolescence and
occasionally even in childhood. As an autosomal dominant
inherited genodermatosis with an estimated incidence of
1:150000 in the general population, BCNS is very rare. It
is characterized by a range of developmental anomalies—
most notably in the head and neck area that allowed the oral
pathologist and dentist Robert Gorlin to describe it ﬁrst -
and a predisposition to various other forms of cancers. Apart
from skeletal abnormalities such as splayed ribs, Sprengel
and pectus deformity, these patients suﬀer from ectopic
calciﬁcation, odontogenic keratocysts, facial dismorphism
with macrocephaly, palmoplantar pits and tumours in terms
of cardiac and ovarian ﬁbroma, meningeoma, medulloblas-
toma, rhabdomyosarcoma, mesenteric cysts, and other neu-
roectodermal tumours [21]. Most prominent among these
clinical ﬁndings is the early and very strong disposition to
develop several, occasionally hundreds of BCCs, especially
after radiation given for treatment of progressive BCC or
medulloblastoma. It was, however, the intensiﬁed research
on BCNS with proof of its cause, a mutated PTCH1 gene in
the majority of cases, that linked cancer to the HH signalling
pathway for the ﬁrst time in 1996 [4, 22].
3.MolecularPathogenesis
3.1. Hedgehog Signalling Pathway. The hedgehog (HH) fam-
ily of intercellular signalling proteins play a pivotal role
in many fundamental processes of embryogenic develop-
ment. They are central to diﬀerentiation, growth, pattering,Journal of Skin Cancer 3
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Figure 2: HH pathway model systems in cancer, adapted from Scales and de Sauvage [26].
morphogenesis, and function of diﬀerent cells and organs
as well as epithelial and mesenchymal tissue interactions in
vertebrates and invertebrates alike [23, 24]. Malfunction or
mutation of these proteins lead to substantial impairment
as already shown by the prickly, hedgehog-like appearing
of mutant ﬂies of Drosophila melanogaster after which
the family of proteins was named. Probably by duplication
of a single-ancestral gene, mammalians, in contrast to
invertebrates with just one HH gene, develop three diﬀerent
types of homologs: the Sonic, the Desert, and the Indian
type. The HH pathway is initiated whenever one of these
ligands binds and thereby inactivates the transmembrane
tumour-suppressor protein patched homologue 1 (PTCH-
1). As a consequence, PTCH-1 then permits its receptor
smoothened (SMO), another transmembrane protein, to
transmit signals to downstream targets by means of the
GLI family of transcription factors. Under normal con-
ditions, and mostly in adults, the hedgehog pathway is
ligand dependent and actively repressed because PTCH-
1 constantly inhibits SMO, the key activator of the GLI
pathway. Especially Sonic hedgehog (SHH), as the most
widely characterized signalling pathway of the three types,
provides a unique example of how the same molecular
cascade leads to diﬀerent pattering in diﬀerent tissue types
solely by distinct transcriptional programs based upon its
local concentration [25]. Inappropriate activation due to
mutations within this cascade however was clearly identiﬁed
by a growing body of evidence to be a pivotal cause of
carcinogenesis, in particular, in BCNS-associated BCCs and
medulloblastoma. According to Scales de Sauvage, so far
three diﬀerent model systems are proposed on how the HH
pathway is involved in the generation of diﬀerent types of
cancer (Figure 2)[ 26].
3.2. Mutations of Hedgehog Signalling Pathway in BCC. Inde-
pendent of the underlying oncogenic mutation, in nearly
all sporadic as well as BCNS-linked BCCs, uncontrolled
stimulations of the hedgehog signalling are found [27, 28].
Due to relatively stable genomes when compared to other
extracutaneous cancer, BCCs routinely carry mutations in
30% to 50% of the tumors in p53 or PTCH-1 [29–31].
The latter either looses thereby its function (loss of function
mutation)orlesscommonlyactivatesSMO(gainoffunction
mutation) [4, 22, 32]. Continuously stimulated by SMO,
a variety of cell-speciﬁc target genes then interfere with
the physiological function via endothelial growth factor and
angiopoetin (resulting in angiogenesis, cell proliferation,
metastasis, and cell survival), ultimately leading to cancer
[26, 33]. SMO itself is mutated only in 10% of all sporadic
BCCs [29]. A few other alternations of the HH pathway, for
example, in SHH or GLI, have been tried to be identiﬁed but
could not be conﬁrmed so far [29, 34].
3.3. Genetic Predispositions, Mutations and Interacting Path-
ways. In view of the known complex interplay of genes and
epigenetic and environmental inﬂuences in carcinogenesis,
the development of BCC and cancer in general is, how-
ever, certainly far more complex and cannot possibly be
reduced to three somatic mutations within the hedgehog4 Journal of Skin Cancer
pathway. With the focus on the downstream target genes and
eﬀects of HH signalling, the BCC carcinogenesis probably
constitutes an intricate mechanism of several interacting
pathways and mutated genes that regulate pigmentation,
DNA repair, and apoptosis. Many other mutations have
been proven to be implicated in BCC so far. Especially the
sequence of downstream mediators in HH seems to diﬀer in
various tissues. Several, such as CD95, BCL-2, PDGFRα,o r
cFLIP, are currently under investigation [35]. Furthermore,
contributions of the FOX gene family, in particular FOXM1
and FOXE1, appear to be involved in downstream signalling
[35–38].AsHHtargetgenes,bothFOXproteinscontrolfora
normal mitosis and are overexpressed in BCC in comparison
to normal keratinocytes [39, 40] .B u ti ti sn o ty e tu n d e r s t o o d
which changes are crucial in BCC and therefore represent
“drivers” but not “passengers” during tumorigenesis of BCC
[14, 41].
A similar lack of knowledge still exists for the interaction
of the GLI signalling pathway with other cellular signals.
The Phosphoinositol-3-kinase (PI3K) cascade interacts with
SHH in at least two ways. While it inhibits protein kinase
A (PKA-) mediated phosphorylation, it also stabilizes GLI2.
On the other hand, SHH activates PI3K, for example, in
prostate cancer [42] .B u tu pt on o w ,n op r o o ff o rP I 3 K
involvement in BCC carcinogenesis could be given [14]. The
relationshipoftheRas/RafsignallingpathwayandBCCisless
welldeﬁned[29].Incomparison,theobviousrequirementof
Wnt signalling in the downstream activation of HH for these
tumours [43] hints at novel possibilities to the therapeutic
approach in BCC in addition to HH inhibitors (described
below) [14].
From a clinical point of view, the most convincing yet
rather confusing—due to several contradicting results—
research focuses on the association of BCC with pigmenta-
tion and DNA repair genes, respectively. At least for sporadic
BCCs as the classic UV-induced variant and those that arise
in patients with xeroderma pigmentosum (XP), a frequent
type of PTCH1 and p53 mutations could be identiﬁed [44].
The clinical presumption that the increased incidence
of BCC in elderly could be a consequence of diminished
DNA repair due to aging seems therefore not so farfetched
[45].Hence,therepairofUV-induceddamageshouldreduce
BCC development [44, 46], although the use of sunscreens
failed to lower the risk of BCC to date [47]. For several
DNA repair gene variants such as XRCC1, XRCC3, XPA,
and XPD, a signiﬁcant association with BCC risk has been
reported [48]. The polymorphism of those mutants involved
is unfortunately reﬂected by diverse and often contradictory
results [49–52]. A variant once proven to be signiﬁcant [48]
was refuted in another study [53] or was, in part, not BCC-
speciﬁc at all [54].
Similarly unpersuasive are the results on melanocortin
1 receptor gene (MCIR), the major known genetic variant
inﬂuencing the degree of skin pigmentation. Although it
was clearly shown that the nonfunctional variant of MCIR
had a dose-dependent impact on the incidence of BCC and
melanoma, the consecutive lack in pigmentation itself did
not inﬂuence the result [54, 55]. A diﬀerent mechanism
in terms of a paracrine role or distant modulation of
proliferation and diﬀerentiation of keratinocytes by MCIR
has also been suggested [56, 57]. In general, the functioning
of pigmentation and DNA repair in healthy individuals, let
alone in skin cancer, is so far too little, or at best partially,
understood in order to pave the way for prevention or let
alone treatment of BCC.
4. Current and Future Treatment Options
4.1. Current Standard of Care. Aw i d er a n g eo fs e v e r a le ﬀec-
tive therapeutic options are available for the therapy of BCC.
Intended to be curative or at least locally controlling, the
treatment can either be surgical or nonsurgical depending
on several tumour- or patient-related factors. Especially
tumour size, location, histological subtype, patient’s health
and wishes, possible complications, and aesthetic results
should be taken into account. As there is still no preoperative
method for the detection of subclinical spread, surgical
therapy with 3D histology is the gold standard even in
BCCs of the head and neck area. In order to ascertain
the complete and hereby curative excision, several equally
eﬀective techniques are at disposal. With Mohs micrographic
surgery, the histological conﬁrmed BCC is removed in a
bowl-like fashion, immediately frozen, and examined for
residual tumour cells in the lateral and basal margins as
long as the BCC is totally excised. 5-year recurrence rates for
Mohs surgery are reported as 1%–3% for primary BCC and
3%–7% for recurrent tumours [58, 59]. Similar results are
achieved with other less known histological methods such
as the La Galette technique [60]. Conventional surgery with
tumour-adapted margins of safety uses a bread loaf horizon-
tal cutting to control for complete excision. Depending on
the safety margin, a higher rate of residual tumour cells and
thus increased recurrence rate of 4%–34% is reported [58].
Curettage, electrodesiccation, and cryosurgery are further
surgical approaches that are easily applied in low-risk lesions
with nonaggressive histological features such as superﬁcial
BCC of the trunk. The disadvantage is, however, that the
complete removal of the BCC cannot be histological proven
and delayed wound healing due to thermal destruction or
impairment of the basal layer may lead to unsatisfactory
results. Certainly, none of these three techniques is appro-
priate for recurrent or morpheaform BCCs, although in
general cure rates of up to 95% and higher are stated [16].
Non-surgical treatment options include radiotherapy, pho-
todynamic therapy, and topical application of imiquimod
and 5-ﬂuorouracil. All of the proposed procedures comprise,
however, the disadvantage that no treatment success can
be histologically validated and thus higher recurrence rates
have to be taken into account. Nonetheless, elderly patients
with multiple comorbidities and inoperable tumours proﬁt.
The indication for radiotherapy—given the multitude of
therapeutic options—is more limited and rather conﬁned to
postoperative recurrences or if a complete resection appears
unlikely. Since there is a high risk of secondary tumors
developing on the radiation side, patients with BCNS, XP,
epidermodysplasia verruciformis, and iatrogenic immuno-
suppression should be excluded from radiotherapy. It isJournal of Skin Cancer 5
Table 1: Current and future HH pathway inhibitors.
SMO-Inhibitors Ongoing trials Indication
GDC-0449
(Erivance, Genentech) Phase II
BCC, medulloblastoma, ovarian cancer, small-cell lung cancer, coloractal
cancer (combined with cisplatin and etoposide), colorectal cancer (in
combination with standard chemotherapy and bevacicumab), and upper
gastrointestinal cancers (in combination with FOLFOLX chemotherapy)
BMS-833923
(Bristol-Myers Squibb and
Exelixis)
Phase I
BCC,BCNS, small lung cancer (versus cisplatin and etoposide), inoperable,
metastatic gastro, gastroesophageal or esophageal Adenocarcinoma
(combined with cisplatin and carpecitabine), and multiple myeloma
IPI-926
Inﬁnity Pharmaceuticals Phase I Advanced and/or metastatic solid tumour malignancies and metastatic
pancreatic cancer (combined with gemcitabine)
LDE-225
(Novartis) Phase I/II
Sporadic superﬁcial and nodular skin BCC, BCNS, medulloblastoma;
rhabdomyosarcoma neuroblastoma, hepatoblastoma, astrocytoma,
advanced solid tumor cancers, and Medulloblastoma
PF-04449913
(Pﬁzer) Phase I select hematologic malignancies or with dasatinib in chronic myeloid
leukemia (CML)
also not recommended for patients younger than 60 years,
given its potential for carcinogenesis [61, 62]. Photodynamic
therapy requires the application of a photosensitizing agent
such as 5-aminolevulinic acid or its ester 3-4 hours before
the protoporphyrin IX-enriched tumour cells are destroyed.
Superior with regards to cosmetic outcome when compared
to many other treatment options, PDT of superﬁcial BCC
showed a 1-year recurrence rate of 9.3% [63] and is not
recommended for the nodal subtype due to 5-year relapse
rates of 76% [64]. Although its precise mechanism is still
unknown, the once-daily application of Imiquimod 5 days
per week for 6 weeks resulted in a histological clearance
rate of up to 89.6% in superﬁcial BCC [65–67]. A clear
trend towards improved rates with increased frequencies
of application is limited by intensiﬁed local and systemic
reactions. Residual tumours after therapy are nonetheless
often diﬃcult to assess, and subtypes other than superﬁcial
BCC are no general indication for Imiquimod since multiple
recurrent lesions can occur [8]. 5-ﬂuorouracil, a topical
cytostatic agent, is considered as a therapeutic alternative
in patients with multiple, superﬁcial multicentric BCCs,
for example, in BCNS [68]. As a consequence of painful
inﬂammatory and erosive reactions, the patient’s compliance
is often limited for this treatment option.
Given that metastasis and invasion of vital structures
by BCC are extremely rare, no therapeutic “gold standard”
exists. Apart from surgical procedures and an additional
radiotherapy, an assortment of diﬀerent chemotherapies
such as doxorubicin, paclitaxel, and/or carboplatin with
diﬀering response rates have been applied up to now in
order to control the tumour load and extend the patient’s life
expectancy [8, 69]. Given the rare nature of metastasis, larger
clinical studies have been lacking until recently.
The more detailed understanding, achieved as of late,
of the molecular pathogenesis of BCC and its causative
aberrant pathway has rendered a new therapeutic targeted
approach possible. SMO inhibitor Cyclopamine, the terato-
genic steroidal plant alkaloid, which was topically applied,
succeeded already to induce regression of four sporadic
BCCs [70], since then, a series of small-molecule HH
inhibitors have been developed and are currently in clinical
development. Furthest along is GDC-0449, a more speciﬁc
and potent SMO inhibitor than Cyclopamine. Administered
in diﬀerent doses of 150, 270, and 540mg per day as part
of a phase I study in metastatic or locally advanced BCC,
an objective response in 18 of 33 patients was achieved
[71]. Side eﬀects such as hyponatraemia, fatigue, weight
loss, and dyspnoea were mild to moderate. Several ongoing
p h a s eI It r i a l si n v e s t i g a t ei t se ﬃcacy in advanced BCC,
medulloblastoma, and breast cancer but also in addition
to other chemotherapeutic agents in pancreatic, lung, col-
orectal, and gastrointestinal cancer. Four other new HH
inhibitors including LDE-225, BMS-833823, IPI-926, and
PF-04449913 are currently under investigation in phase I
trials. All of the tested components target so far SMO as
the key regulator of the HH pathway. An equally eﬀective
inhibition could succeed, however, in targeting the HH
downstream signalling. Two tested candidates GANT58
and GANT61, inhibitors of the GLI transcription, possibly
provide a therapeutic alternative in case of a resistance to
SMO inhibitors [72]. Also interfering with HH target gene
transcription and therefore of potential therapeutic interest
in BCC is the new ﬁeld of microRNAs. While one single
microRNA regulates hundreds of target genes, the task is to
focus its eﬃcacy on the essential target and thus minimize its
side eﬀects, which still needs to be mastered (Table 1)[ 73].
As discussed by Epstein, the use of tyrosine kinase
inhibitors, sorafenib or imatinib, seems sensible because
PDGFRα is supposed to mediate downstream eﬀects in HH
signalling [14]. The assortment of further new potential
agentsforpreventionaswellastreatmentinBCCisplentiful,
ranging from Vitamin A and D derivates, NSAID, and DNA
repair enzymes up to Melanocortin peptides therapeutics.
Certainly due to the lack of knowledge of their precise func-
tioning and how, or if at all, they interact with HH pathway,
resultsaresofarpromisingbutinconclusive.Itmaytherefore
not be surprising that even the widely recognized and in its
molecular eﬀects initially well understood standard therapy
with systemic retinoids fails to prevent the recurrence of
sporadic BCC [74].6 Journal of Skin Cancer
5. Conclusion
In view of those remarkable oncogenomic achievements
in the understanding of BCC carcinogenesis, a curative
breakthrough, especially in hereditary, locally advanced or
metastatic cases, seems imminent. First promising data are
yet too scarce to obtain detailed pieces of information about
dosage, side eﬀects, response, recurrence, and survival rates
or possible medical interactions. Not suﬃciently known but
crucial is certainly the impact of the type of HH mutations
and their combinations for the various clinical subtypes of
BCC. The change from a phenotype-correlated diagnosis to
a genotype analysis, at least in advanced tumours, is obvious.
But is BCC in all its clinical and histological variations to
be reclassiﬁed according to its genotype? Genetic analysis
will undoubtedly change the classiﬁcation and subsequently
treatment algorithms for BCC. The open intruiging question
remains if there is a link between HH mutation, histology,
and its clinical aspects that would simplify the indication
for a targeted therapy. Of equal importance in this complex
interplay are without doubt epigenetic phenomena and envi-
ronmental factors that are at best only initially recognized so
far.Deﬁnitelymanymorefuturestudiesareneededtoanswer
the large number of interesting questions that the discovery
of aberrant HH pathway for BCC raised.
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